Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases

BMC Cancer
Surabhi RanjanJing Wu

Abstract

Immune checkpoint inhibitors (ICPIs) are being investigated in clinical trials for patients with glioblastoma. While these therapies hold great promise, management of the patients receiving such treatment can be complicated due to the challenges in recognizing immune-related adverse events caused by checkpoint inhibitor treatment. Brain imaging changes that are the consequence of an inflammatory response may be misinterpreted as disease progression leading to inappropriate premature cessation of treatment. The aim of this study was to, by way of a series of cases, underscore the challenges in determining the nature of contrast-enhancing masses that develop during the treatment of patients with glioblastoma treated with ICPIs. We reviewed the clinical course and management of 4 patients on ICPIs who developed signs of tumor progression on imaging. These findings were examined in the context of Immunotherapy Response Assessment in Neuro-Oncology (iRANO) guidelines. Although all 4 patients had very similar imaging findings, 2 of the 4 patients were later found to have intense inflammatory changes (pseudoprogression) by pathologic examination. A high index of suspicion for pseudoprogression needs to be maintained when a patient wit...Continue Reading

References

Jan 11, 2001·The New England Journal of Medicine·L M DeAngelis
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
May 3, 2008·The Lancet Oncology·Dieta BrandsmaMartin J van den Bent
Jul 25, 2008·Proceedings of the National Academy of Sciences of the United States of America·Gordon J Freeman
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Dec 1, 2009·Neurosurgery Clinics of North America·Isaac YangAndrew T Parsa
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jul 2, 2014·Journal of the Neurological Sciences·Jacob J MandelIvo W Tremont-Lukats
Sep 6, 2014·Neuro-oncology·David A ReardonGlenn Dranoff
Oct 31, 2014·Neuro-oncology·Anna Sophie BerghoffWolfgang Wick
Apr 1, 2015·Clinical Therapeutics·Kathleen M MahoneyDavid F McDermott
Jul 1, 2015·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·I-Wen PanSandi Lam
Sep 2, 2015·Neuro-oncology·Edjah K NduomAmy B Heimberger
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NaidooJ D Wolchok
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Oct 31, 2015·Neuro-oncology·Edjah K NduomAmy B Heimberger
Nov 8, 2015·The Lancet Oncology·Hideho OkadaDavid A Reardon
Mar 10, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F Stephen HodiJedd D Wolchok
Jul 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sophie Cousin, Antoine Italiano

❮ Previous
Next ❯

Citations

Jan 16, 2020·Journal of the Royal Society, Interface·Prativa SahooRussell C Rockne
Mar 7, 2020·Ophthalmic Plastic and Reconstructive Surgery·Giancarlo A GarciaAndrea L Kossler
Apr 10, 2020·Future Oncology·Vincenzo Di NunnoAlba Ariela Brandes
Jun 1, 2020·Journal for Immunotherapy of Cancer·John P LynesEdjah K Nduom
Dec 21, 2018·Frontiers in Oncology·John LynesEdjah Nduom
Jan 4, 2019·Journal of Neuro-oncology·Martin VossStella Breuer
Sep 19, 2020·Expert Opinion on Investigational Drugs·Gilbert Youssef, Jorg Dietrich
Jun 7, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robin A BuerkiHideho Okada
Jan 29, 2021·Neuro-oncology Advances·Nivedita M RatnamMark R Gilbert
Mar 30, 2020·Molecular Therapy : the Journal of the American Society of Gene Therapy·Carolini KaidMayana Zatz
Feb 22, 2021·Journal of Neuro-oncology·Hok Yee ChanMichael Lim
Jun 15, 2021·Interface Focus·Gabriel Emilio Herrera-OropezaKatia Aviña-Padilla
Aug 3, 2021·Frontiers in Oncology·Nivedita M RatnamMark R Gilbert

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
imaging techniques

Clinical Trials Mentioned

NCT02311920

Software Mentioned

iRANO

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.